Go Deep
Cohance Lifesciences Limited
Cohance Lifesciences Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 24,003 | 162.1 | 4.33 | 0.10 | 442.40 |
| Oct 2026 | 23,430 | 161.5 | 4.31 | 0.10 | 441.00 |
Cohance Lifesciences Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 4,222,600,000.0 | 6,191,200,000.0 | 5,445,500,000.0 | 5,555,700,000.0 |
| Net Profit | -241,200,000.0 | 195,500,000.0 | 367,200,000.0 | 740,800,000.0 |
| EPS | -0.6 | 0.5 | 1.0 | 1.9 |
Cohance Lifesciences Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 22,038,100,000.0 | 25,262,200,000.0 | 10,340,600,000.0 | 13,311,101,000.0 | — |
| Net Profit | 1,792,300,000.0 | 4,873,400,000.0 | 3,002,800,000.0 | 4,112,900,000.0 | — |
| EPS | 4.7 | 12.8 | 11.8 | 16.2 | — |
Cohance Lifesciences Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 57,296,400,000.0 | 54,809,600,000.0 | 22,549,100,000.0 | 19,657,438,000.0 | — |
| Total Liabilities | 16,958,100,000.0 | 16,880,800,000.0 | 2,042,400,000.0 | 2,305,595,000.0 | — |
| Total Equity | 39,112,910,000.0 | 36,488,200,000.0 | 20,506,700,000.0 | 17,351,843,000.0 | — |
Owes vs Owns
Cohance Lifesciences Limited owed ₹0.30 for every ₹1 it owned in Mar 2026, up from ₹0.12 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.30× | 0.31× | 0.09× | 0.12× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Cohance Lifesciences Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 5.6%Receivables 11.9%Inventory 9.8%Fixed assets (tangible) 37.9%Intangible assets 24.1%Long-term investments 4.7%Other assets 6.0%
How it's funded — Mar 2026
Short-term debt 2.1%Long-term debt 0.9%Payables 5.0%Other liabilities 21.7%Shareholders' equity 70.4%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 320.1 | 297.9 | 821.1 | 483.7 |
| Receivables | 681.0 | 772.1 | 133.7 | 110.9 |
| Inventory | 562.2 | 467.4 | 231.2 | 312.8 |
| Fixed assets (tangible) | 2,169.9 | 2,103.2 | 788.5 | 769.5 |
| Intangible assets | 1,383.2 | 1,345.3 | 61.9 | 62.2 |
| Long-term investments | 268.0 | 145.8 | 130.6 | 117.1 |
| Other assets | 345.2 | 349.3 | 87.9 | 109.5 |
| Liabilities & equity | ||||
| Short-term debt | 119.2 | 128.6 | 38.6 | 64.6 |
| Long-term debt | 50.5 | 129.8 | 0.0 | 4.6 |
| Payables | 284.6 | 268.4 | 42.4 | 70.1 |
| Other liabilities | 1,241.6 | 1,161.3 | 123.3 | 91.3 |
| Shareholders' equity | 4,033.8 | 3,792.9 | 2,050.7 | 1,735.2 |
| Net tangible assets | 2,528.1 | 2,303.5 | 1,988.7 | 1,673.0 |
Cohance Lifesciences Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 3,683,200,000.0 | 6,733,500,000.0 | 3,847,700,000.0 | 4,571,958,000.0 | — |
| Investing Activities | -2,545,700,000.0 | -3,897,000,000.0 | -3,623,500,000.0 | -1,950,056,000.0 | — |
| Financing Activities | -1,651,500,000.0 | -3,274,000,000.0 | -399,900,000.0 | -2,419,512,000.0 | — |